John Marshall, ASCO GI22: Immune Checkpoint Inhibitors and Neoadjuvant Treatment Options for Oesophageal Cancer
touchONCOLOGY were thrilled to speak to Editorial Board member Professor John Marshall (Medstar Georgetown University Hospital, Washington, DC, USA) to summarise the latest developments and data from the ASCO Gastrointestinal Cancers Symposium 2022.
The phase III CheckMate 577 Study (NCT03044613): https://meetings.asco.org/abstracts-presentations/204867
KEYNOTE-062 (NCT02494583): https://meetings.asco.org/abstracts-presentations/204515
JCOG NExT study (UMIN000014795): https://meetings.asco.org/abstracts-presentations/204882
Questions:
- What have recent clinical study data taught us about the optimal front-line use of immune checkpoint inhibitors in advanced gastro-oesophageal cancer? 00:16-02:50
- Could you tell us a little about the JCOG NExT study and its implications for the future neoadjuvant treatment for locally advanced esophageal cancer? 02:50-05:21
Speaker Disclosure: John Marshall has no conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ASCO Gastrointestinal Cancers Symposium 2022.
